Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: Coprecipitants or coincidence? [3]

American Journal of Gastroenterology

Volumn 97, Issue 4, 2002, Pages 1061-1062

  Goh, Jason ^a   Wight, Derek ^a   Parkes, Miles ^a   Middleton, Stephen J ^a   Hunter, John O ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

AGED; ANTIINFLAMMATORY ACTIVITY; CASE REPORT; COLITIS; CROHN DISEASE; CYTOMEGALOVIRUS; DRUG EFFICACY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 0036117961     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)03987-4     Document Type: Letter

References (6)

1. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease
2. Cyclooxygenase 2 - Implications on maintenance of gastric integrity and ulcer healing: Controversial issues and perspectives
3. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib, placebo and indomethacin
4. Exacerbation of inflammatory bowel disease associated with use of celecoxib
5. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis
6. Selective COX-2 inhibitors and human inflammatory bowel disease